At Ligand, we seek to identify high-value, risk-mitigated biopharmaceutical assets. We take a systematic and disciplined approach to investing to create a diversified portfolio of programs that produce consistent and predictable revenue streams for our shareholders.
We acquire existing royalty contracts from inventors, universities, and non-strategic assets from biopharmaceutical companies. Today, our portfolio consists of more than 85 different programs and includes economic rights to some of the most impactful medicines in the world.
Asset Selection Criteria
- Strong clinical differentiation
- Addresses unmet need
- Solid patent protection
- Time to market
- Therapeutically agnostic